Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: Largest safe dose using a risk-adapted approach

Journal of Nuclear Medicine

Volumn 44, Issue 3, 2003, Pages 451-456

  Dorn, Robert ^a   Kopp, Juergen ^a   Vogt, Harry ^a   Heidenreich, Peter ^a   Carroll, Robert G ^b   Gulec, Seza A ^c  

^a Department of Trauma and Reconstructive Surgery   (Germany)

^b University Community Hospital Tampa   (United States)

^c JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

131I therapy; Dosimetry; Largest safe dose; Thyroid cancer

Indexed keywords

IODINE 131; RADIOACTIVE IODINE;

ARTICLE; BONE MARROW; CONTROLLED STUDY; DOSIMETRY; HEMATOLOGY; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; RADIATION DOSE; RADIOISOTOPE THERAPY; RETROSPECTIVE STUDY; RISK ASSESSMENT; THYROID CARCINOMA; TREATMENT OUTCOME; ADOLESCENT; ADULT; AGED; BONE TUMOR; CARCINOMA; CHILD; FEMALE; LUNG TUMOR; MALE; MIDDLE AGED; PATHOLOGY; PRESCHOOL CHILD; RADIATION EXPOSURE; THYROID TUMOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BONE MARROW; BONE NEOPLASMS; CARCINOMA; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IODINE RADIOISOTOPES; LUNG NEOPLASMS; MALE; MIDDLE AGED; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; THYROID NEOPLASMS;

EID: 0037361835     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Seidlin SM, Marinelli LD, Oshry E. Radioactive iodine therapy: effect on functioning metastases of adenocarcinoma of thyroid. JAMA. 1946;132:838-847.
2. Benua RS, Cicale NR, Sonenberg M, Rawson RW. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. AJR 1962;87:171-182
3. Benua RS, Leeper RD. A method and rationale for treating thyroid carcinoma with the largest safe dose of I-131. In. Meideros-Neto GA, Gaitan E, eds Frontiers of Thyroidology. Vol. II. New York, NY: Plenum; 1986:1317-1321
4. Loevinger R, Budinger TF, Watson EE, in collaboration with the MIRD Committee. MIRD Primer for Absorbed Dose Calculations. New York, NY: The Society of Nuclear Medicine; 1988.
5. Beierwaltes WH. Update on basic research and clinical experience with metaiodobenzylguanidine. Med Pediatr Oncol. 1987;15:163-169.
6. Rao DV, Howell RW. Time-dose-fractionation in radioimmunotherapy, implications for selecting radionuclides. J Nucl Med. 1993;34:1801-1810
7. Kolbert KS, Sgouros G, Scott AM, et al. Implementation and evaluation of patient-specific three-dimensional dosimetry. J Nucl Med. 1997:38 301-308.
8. Akabani G, Hawkins WG, Eckblade MB, Leichter PK. Patient-specific dosimetry using quantitative SPECT imaging and three-dimensional discrete Fourier transform convolution. J Nucl Med. 1997;38:308-314
9. Furhang EF, Larson SM, Buranapong P, Humm JL. Thyroid cancer dosimetry using clearance fitting. J Nucl Med. 1999;40:131-136.
10. Mazzaferri EL. Long-term outcome of patients with differentiated thyroid carcinoma: effect of therapy. Endocr Pract. 2000;6:469-476
11. Taylor T, Speckler B, Robbins J, et al. Outcome after treatment of high risk papillary and non-Hurthle-cell follicular thyroid carcinoma. Ann Intern Med. 1998;129:622-627
12. VanNostrand D, Neutze J, Atkins F. Side effects of "rational" iodine-131 therapy for metastatic well-differentiated thyroid carcinoma. J Nucl Med. 1986;27:1519-1527.
13. Thomas SR, Samaratunga RC, Sperling M, Maxon HR. Predictive estimate of blood dose from external counting data preceding radioiodine therapy for thyroid cancer. Nucl Med Biol 1993;20:157-162
14. 131I imports less absorbed radiation to thyroid cancer than predicted by dosimetry [abstract]. Thyroid 1994;4:S-61
15. Stabin MG. MIRDOSE personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 1996;37:538-546.
16. 131I. Proceedings, Sixth International Radiopharmaceutical Dosimetry Symposium Gatlinburg, TN: Oak Ridge Associated Universities; 1999.137-139.
17. Beierwaltes WH, Nishiyama RH, Tompson NW, Copp JE, Kubo A. Survival time and "cure" in papillary and follicular thyroid carcinoma with distant metastases statistics following University of Michigan therapy. J Nucl Med. 1982;23:561-568
18. Maxon HR, Thomas SR, Samaratunga RC. Dosimetric considerations in the radioiodine treatment of macrometastases and micrometastases from differentiated thyroid cancer. Thyroid. 1997;7:183-187.
19. Miller RC, Hiraoka T, Kopecky KJ, et al. Sensitivity to radiation of normal, hyperthyroid, and neoplastic thyroid epithelial cells in primary culture. Radiat Res 1987;111:81-91.
20. Maxon HR. Quantitative radioiodine therapy in the treatment of differentiated thyroid cancer. Q J Nucl Med. 1999;43:313-323.
21. Flower MA, Schlesinger T, Hinton PJ, et al. Radiation dose assessment in radioiodine therapy. 2. Practical implementation using quantitative scanning and PET, with initial results on thyroid carcinoma. Radiother Oncol 1989;15:345-357.
22. Guenter H-H, Schober O, Schwarzrock R, Hundeshagen H, Hematologic long-time modifications after radioiodine therapy of the carcinoma of the thyroid gland. II Modifications of the bone marrow including leukemia [in German]. Strahlenther Onkol 1987;163:475-485.